IR@PKUHSC  > 北京大学基础医学院  > 病原生物学系
学科主题基础医学
Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients
Yang, Jing-Xian1; Liu, Bao-Ming1; Li, Xiao-Guang2; Yan, Chun-Hui1; Xu, Jie2; Sun, Xie-Wen3; Wang, Yu-Hua3; Jiao, Xiu-Juan3; Yan, Ling1; Dong, Jan-Ping4; Hou, Chun-Sheng5; Abuduheilili, Xiernayi6; Li, Tong1; Zhuang, Hui1
刊名ANTIVIRAL THERAPY
2010
DOI10.3851/IMP1677
15期:8页:1171-1178
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Infectious Diseases ; Pharmacology & Pharmacy ; Virology
研究领域[WOS]Infectious Diseases ; Pharmacology & Pharmacy ; Virology
关键词[WOS]ADEFOVIR DIPIVOXIL ; ENTECAVIR RESISTANCE ; VIRUS POLYMERASE ; DRUG-RESISTANCE ; TREATMENT FAILURE ; IN-VITRO ; LAMIVUDINE ; TENOFOVIR ; THERAPY ; SUBSTITUTIONS
英文摘要

Background: Antiviral drug-resistant HBV mutants under a variety of treatment protocols are complex and only partly understood. Here, a population-based cross-sectional study was performed to analyse the profile of resistance mutations in distinct evolutionary pathways refractory to different nucleoside/nucleotide analogues (NAs).

Methods: Serum samples of 199 chronic hepatitis B patients undergoing NA treatment from five hospitals in four northern cities of China were obtained between January 2007 and July 2009. The genotypic resistance of HBV in these samples was characterized. The full-length HBV reverse transcriptase region was amplified, sequenced and analysed with particular focus on the following NA-resistant changes: rtL80, rtI169, rtV173, rtL180, rtA181, rtT184, rtA194, rtS202, rtM204, rtN236 and rtM250.

Results: Among 199 HBV isolates, 30 (15.08%) and 169 (84.92%) were genotypes B and C, respectively, and 65 (32.66%) harboured NA-resistant mutations. The prevalence of mutations at rtM204 was 34.33% in 134 patients who had received or who had been exposed to lamivudine-based therapy. Five cases of rtN236 mutations were detected exclusively among 75 patients receiving adefovir-dipivoxil-based therapies. A total of 19 cases of multidrug resistance rtA181 mutations were observed in those with lamivudine-, adefovir-dipivoxil-or telbivudine-based treatment (186 cases), but not in those undergoing entecavir treatment (13 cases). Mutations were not found at rtI169, rtT184, rtA194 or rtS202. rtM204 mutations (27 rtM204I, 15 rtM204V and 5 rtM204I/V cases) were detected at the highest frequency among 65 mutants (72.30% [47/65]) and found to display 16 combination mutation patterns, in which rtM204I and rtM204V were significantly associated with rtL80I/V and rtL180M, respectively (P<0.01).

Conclusions: One-third of the studied population harboured NA-resistant HBV with complicated mutation patterns. Monitoring HBV genotypic resistance mutation markers and patterns is therefore shown to be beneficial for optimizing antiviral therapies and for avoiding clinical deterioration.

语种英语
WOS记录号WOS:000287431200012
项目编号2005CB523104 ; 2008ZX10002-004 ; 2009ZX10004-314
资助机构Chinese National Key Basic Research Project ; Major Science and Technology Special Project of China Eleventh Five-year Plan
引用统计
被引频次:21[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
版本出版稿
条目标识符http://ir.bjmu.edu.cn/handle/400002259/67694
专题北京大学基础医学院_病原生物学系
作者单位1.Qinhuangdao Third Hosp, Dept Infect Dis, Qinhuangdao, Peoples R China
2.Beijing Haidian Hosp, Dept Infect Dis, Beijing, Peoples R China
3.Peking Univ, Hlth Sci Ctr, Dept Microbiol, Beijing 100871, Peoples R China
4.Peking Univ, Hosp 3, Dept Infect Dis, Beijing 100871, Peoples R China
5.Shandong Jining Infect Dis Hosp, Dept Infect Dis, Jining, Peoples R China
6.Xinjiang Med Univ, Affiliated Hosp 1, Dept Infect Dis, Urumqi, Peoples R China
推荐引用方式
GB/T 7714
Yang, Jing-Xian,Liu, Bao-Ming,Li, Xiao-Guang,et al. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients[J]. ANTIVIRAL THERAPY,2010,15(8):1171-1178.
APA Yang, Jing-Xian.,Liu, Bao-Ming.,Li, Xiao-Guang.,Yan, Chun-Hui.,Xu, Jie.,...&Zhuang, Hui.(2010).Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.ANTIVIRAL THERAPY,15(8),1171-1178.
MLA Yang, Jing-Xian,et al."Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients".ANTIVIRAL THERAPY 15.8(2010):1171-1178.
条目包含的文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
Profile of HBV antiv(221KB)期刊论文出版稿开放获取CC BY-NC-SA浏览 请求全文
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Yang, Jing-Xian]的文章
[Liu, Bao-Ming]的文章
[Li, Xiao-Guang]的文章
百度学术
百度学术中相似的文章
[Yang, Jing-Xian]的文章
[Liu, Bao-Ming]的文章
[Li, Xiao-Guang]的文章
必应学术
必应学术中相似的文章
[Yang, Jing-Xian]的文章
[Liu, Bao-Ming]的文章
[Li, Xiao-Guang]的文章
相关权益政策
暂无数据
收藏/分享
文件名: Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside nucleotide analogue treatment among Chinese chronic hepatitis B patients.pdf
格式: Adobe PDF
此文件暂不支持浏览
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。